Part II: FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide: How the April 30 Proposal Kills the Compounded GLP-1 Supply Chain and Draws a Hard Line Between Clinical Need and Economic Need

Thoughts on Healthcare Markets & Technology Podcast

0:00

-12:09

Paid episode

The full episode is only available to paid subscribers of Thoughts on Healthcare Markets & Technology

Part II: FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide: How the April 30 Proposal Kills the Compounded GLP-1 Supply Chain and Draws a Hard Line Between Clinical Need and Economic Need

On April 30, 2026, FDA proposed excluding the three major GLP-1 drugs from the 503B bulks list — here is exactly what that does and who it kills.

May 04, 2026

∙ Paid

Quick Links: Knowledge Base, Podcast, and Social

Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech

Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive including subscriber-only epi…

Continue reading this post for free, courtesy of Thoughts on Healthcare.

Or purchase a paid subscription.